Marksans Pharma Share Price Target 2024, 2025, 2030, 2040, 2050
Marksans Pharma Ltd is an Indian company that makes and sells medicines in different countries. They have branches in the UK and the US, and they sell their medicines in many countries.
What is Marksans Pharma Ltd NSE: MARKSANS?
Contents
- 1 What is Marksans Pharma Ltd NSE: MARKSANS?
- 2 Marksans Pharma Share Price Target 2024
- 3 Marksans Pharma Share Price Target 2025
- 4 Marksans Pharma Share Price Target 2030
- 5 Share Price Target 2040
- 6 Share Price Target 2050
- 7 Should I Buy Marksans Pharma Stock?
- 8 Marksans Pharma Ltd Earning Results
- 9 Is Marksans Pharma Stock Good to Buy? (Bull case & Bear case)
- 10 Bull Case:
- 11 Bear Case:
- 12 Conclusion
- 13 FAQs
Marksans Pharma Ltd is a company that makes and sells medicines. They make medicine for heart problems, brain and nerve conditions, diabetes, pain, cancer, infections and more. Besides these, they provide prescription medicines for heart and nerve health, cancer, diabetes, and infections.
They are not only limited to India to sell its products but also supply it to different countries. They have multiple branches in the outside of the country. Most of their income comes from the United States and North America.
The company has excellent factories and makes high-quality medicines. They make medicines for different health issues like cancer, stomach problems, diabetes, infections, heart issues etc. The company plans to make more types of medicines, so their business is likely to grow even more in the future. Their sales and profits are growing each year. Because of this, the company is expected to do well in the near future. In 2024 360 rs would be the price target as per our analysis.
| Year | Minimum Price | Maximum Price |
| 2024 | 149 | 360 |
| Month | Minimum Price | Maximum Price |
| January | 140 | 180 |
| February | 138 | 170 |
| March | 130 | 157 |
| April | 152 | 185 |
| May | 144 | 175 |
| June | 130 | 166 |
| July | 160 | 222 |
| August | 164 | 240 |
| September | 170 | 276 |
| October | 221 | 320 |
| November | 242 | 340 |
| December | 265 | 360 |
This company is growing its business in India and many other countries. They are also starting to work with big drug companies in the US and Europe to make and sell different medicines. Their main goal is to become strong in the US market for generic drugs. They are also looking into new markets. With their current plans and team, the company might give better returns to investors by 2025, we can expect 430 rs as a price target this year.
| Year | Minimum Price | Maximum Price |
| 2025 | 240 | 430 |
| Month | Minimum Price | Maximum Price |
| January | 240 | 310 |
| February | 245 | 315 |
| March | 255 | 320 |
| April | 255 | 335 |
| May | 260 | 360 |
| June | 268 | 370 |
| July | 265 | 385 |
| August | 260 | 392 |
| September | 250 | 400 |
| October | 270 | 410 |
| November | 289 | 425 |
| December | 277 | 430 |
The company is expanding its range of generic drugs and antibiotics to keep up with growing customer needs. companies have been able to produce affordable generic drugs to meet increasing demand. The company is growing its production and will benefit the Indian medicine drug market. Also, it always focused on Research & Development to create and improve new products. So in 2030, the price target would be 1600 rs.
| Year | Minimum Price | Maximum Price |
| 2030 | 1200 | 1600 |
| Month | Minimum Price | Maximum Price |
| January | 1200 | 1320 |
| February | 1215 | 1300 |
| March | 1225 | 1328 |
| April | 1232 | 1350 |
| May | 1260 | 1390 |
| June | 1280 | 1410 |
| July | 1350 | 1470 |
| August | 1466 | 1500 |
| September | 1470 | 1510 |
| October | 1490 | 1540 |
| November | 1520 | 1570 |
| December | 1560 | 1600 |
The company makes medicines for the major disease. It always has good quality with better pricing. It is always spent on research to do better. Also, the company expands its business by including small companies to own companies. This will make it a big company and there will be fewer competitors in the market. So, we could expect 3620 rs as the price target in 2040.
| Year | Minimum Price | Maximum Price |
| 2040 | 2800 | 3620 |
| Month | Minimum Price | Maximum Price |
| January | 2800 | 2920 |
| February | 2850 | 2900 |
| March | 3000 | 3200 |
| April | 3120 | 3340 |
| May | 3200 | 3400 |
| June | 3270 | 3430 |
| July | 3300 | 3440 |
| August | 3390 | 3460 |
| September | 3400 | 3500 |
| October | 3480 | 3520 |
| November | 3520 | 3600 |
| December | 3570 | 3620 |
The company is developing new products each year to help its business grow, and this should lead to significant growth in the future. The Indian government is also helping local manufacturers with different programs. This company is increasing its production quickly to take advantage of this support, which will help its business grow even faster. The company had great brand value outside the country too. It had many branches in different parts of the world, so it had a bright feature. in 2050, the price target would be 6000 rs.
| Year | Minimum Price | Maximum Price |
| 2050 | 4900 | 6000 |
| Month | Minimum Price | Maximum Price |
| January | 4900 | 5100 |
| February | 4960 | 5180 |
| March | 4990 | 5200 |
| April | 5000 | 5190 |
| May | 5060 | 5200 |
| June | 5100 | 5330 |
| July | 5200 | 5410 |
| August | 5380 | 5500 |
| September | 5400 | 5660 |
| October | 5540 | 5790 |
| November | 5700 | 5870 |
| December | 5840 | 6000 |
Should I Buy Marksans Pharma Stock?
| Year | Minimum Price | Maximum Price |
| 2024 | 149 | 360 |
| 2025 | 240 | 430 |
| 2030 | 1200 | 1600 |
| 2040 | 2800 | 3620 |
| 2050 | 4900 | 6000 |
The company has top competitors in the pharmaceutical industry. Every year they spend much money to do research to do better. They are very well-known outside the country too. The company has good potential to grow in the future. So, If you’re planning to invest for the long term and want to take advantage of this growth, then you can take a risk in this stock.
Marksans Pharma Ltd Earning Results
| Market Capital | 8,578.39 Crore |
| Revenue (TTM) | 2,177.4 Crore |
| Net Income (TTM) | +313.69 Crore |
| Operating Margin | 15.81% |
| Profit Margin | 14.4% |
| Revenue Growth (Quarterly) | +15.2% |
| Earnings Growth (YOY Quarterly) | -5.3% |
| Debt-to-Equity (D/E) Ratio | 11.7 |
| Total Debt | 244.06 Crore |
| Total Cash | 700.57 Crore |
| Beta | 1.65 |
Is Marksans Pharma Stock Good to Buy? (Bull case & Bear case)
Bull Case:
- India is becoming a big player in the pharmaceutical industry, and Marksans Pharma could benefit from this.
- The company is adding new products and increasing its production, which might lead to more growth.
- Marksans Pharma is getting support from government programs for local businesses.
- This company spread not only within India but also had branches in different parts of the world.
Bear Case:
- There’s a lot of competition in the industry, which could impact the company.
- The pharmaceutical industry can be unpredictable, and there might be challenges.
Conclusion
So, we have discussed in depth about this stock. This company is very old it was established in 1992. It had a great business in India and outside of the country too. The company plans to include the small company in its own sector to grow the company. Also, it spends money on research and development for a better future.
